Impression Healthcare Limited (ASX: IHL)
Dental services provider, Impression Healthcare Limited recently executed an exclusivity agreement with RespireRx for the use of Dronabinol for Obstructive Sleep Apnoea in New Zealand, Australia and SE Asia.
The agreement outlines the extension to the company’s current dronabinol project and the existing distribution of the Sleep Guardian mandibular advancement device. The use of dronabinol is aimed at the treatment of Obstructive Sleep Apnoea which is faced by approximately 4% of men and women in Australia due to an ageing population and obesity.
Dronabinol is positioned as easy to take with a low side-effect profile. Impression stated that it had secured this agreement to tap the growing OSA market which was valued at US$5.5billion in 2017 worldwide.
For the half year ended 31 December 2018, the company reported a loss of $1.29 million from ordinary activities, compared to the loss of $1.21 million in the previous corresponding period. The Group also commenced the consolidation of its operating activities by shutting down its Adelaide office and transferring those activities to Melbourne. This consolidation program is expected to be completed in Q1 of 2019 when the Adelaide lease arrangements complete.
IHL shares closed at A$0.018 on 28 February 2019.
Orthocell Limited (ASX: OCC)
Orthocell Limited, a regenerative medicine company focused on developing products for the repair of soft tissue injuries, achieves 82% success rate for the quality of TGA-licensed cell therapies Autologous Tenocyte Implantation (Ortho-ATI®). The product is used for the treatment of chronic tendon injuries including the treatment to shoulder, elbow, hip, knee and ankle tendons.
In the company’s annual quality study, 82% of patients suffering from the chronic tendon injuries gave their feedback to ‘extremely satisfied’, ‘very satisfied’, and ‘satisfied’ for reduction of pain and overall improvement by using Ortho-ATI® stem cell therapy.
Moreover, the biotech player recently completed $1.8 million capital raising via a share placement to professional and sophisticated investors across Australia and Asia, including existing shareholders. Orthocell intends to utilise the proceeds raise from placement to accelerate the market entry of CelGro® for dental bone and soft tissue repair into European markets.
OCC stock last traded at A$0.130 on 28 February 2019.
Althea Group Holdings Limited (ASX: AGH)
Medicinal cannabis company, Althea Group Holdings Limited (ASX: AGH) recently inked a product supply and distribution agreement with private company Cannvalate for its medicinal cannabis products in Australia.
Cannvalate, appointed as non-exclusive distributor of Althea’s medicinal cannabis products, is one of Australia’s widest network company in medicinal cannabis sector prescribing clinics spanning all states of Australia.
For full-year 2019, the company presented optimistic outlook towards the reach of its medicinal cannabis’ products as it focuses on employing more people to educate doctors and implement innovative ways for them to learn more about Althea’s range of medicinal cannabis.
Moreover, Althea’s Concierge medical education platform reportedly continues to grow with 165 registered Healthcare Professionals signing up, which is considered a crucial first step to becoming an Althea medicinal cannabis prescriber.
AGH stocks last traded at A$0.425 on 27 February 2019.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.